•  
• Tweet
•  
•  
•        Print
•  
•        Email
•  
•         Track Keywords

Between January and March 2020, the total value of global venture-backed healthtech deals jumped by 76% from Q1 2019 reaching $8.2bn, the highest quarterly total on record. Activity has been dominated by North America, comprising 56% of the total number of deals, followed by Europe with 21% and Asia with 17%.

The largest venture-backed healthtech deal completed in Q1 2020 was the $285mn Series E financing held by ClassPass Inc. This momentum has continued into Q2, with a further $3.2bn in healthtech deals made since the start of April - at this pace, 2020 will be a record year for the sector by some distance.

Christopher Beales, Private Equity Spokesperson: "Healthtech was already an area of some interest to venture capital investors, as Preqin discussed at the start of the year. But the COVID-19 pandemic has thrown the potential of the sector into sharp relief. Remote consultations, prescription delivery, digital therapeutic and wellness classes - demand for next-generation healthcare solutions has boomed. As such, startups and investors are jumping to try and meet that need, and a sector that was already expanding has been given a real shot of adrenaline."

Key Healthtech Deals Facts:

• In our April 2020 survey of over 100 investors active in alternative assets, 36% said that they are targeting healthcare-focused investments in 2020 because of COVID-19's impact.

• Global venture-backed healthcare deal value increased from $4.7bn in Q1 2019, to $8.2 in Q1 2020.

• Regionally, in Q1 2020, 239 deals were completed in North America, 87 in Europe and 73 in Asia.

• The largest venture-backed healthtech deal completed in Q1 2020 was the $285mn Series E financing held by ClassPass Inc.

• In Q2 2020, as at 18th May 2020, 158 healthtech deals have been completed with a value of $3.2bn.

Article source - Opalesque is not responsible for the content of external internet sites